Keisuke Shigeta, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Transitional Cell | 20 | 2024 | 789 | 5.990 |
Why?
|
Ureteral Neoplasms | 11 | 2024 | 106 | 5.490 |
Why?
|
Urologic Neoplasms | 9 | 2024 | 312 | 4.310 |
Why?
|
Urinary Bladder Neoplasms | 29 | 2024 | 2176 | 4.130 |
Why?
|
Laparoscopy | 8 | 2023 | 2037 | 1.570 |
Why?
|
Taxoids | 4 | 2024 | 665 | 1.100 |
Why?
|
Kidney Neoplasms | 7 | 2024 | 4278 | 1.000 |
Why?
|
Nephrectomy | 3 | 2023 | 927 | 0.990 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2023 | 9373 | 0.940 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2024 | 109 | 0.860 |
Why?
|
Mucin-1 | 3 | 2024 | 535 | 0.830 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1056 | 0.770 |
Why?
|
Watchful Waiting | 2 | 2019 | 492 | 0.760 |
Why?
|
Cystectomy | 8 | 2024 | 603 | 0.570 |
Why?
|
Sutures | 1 | 2019 | 283 | 0.570 |
Why?
|
Erectile Dysfunction | 1 | 2020 | 437 | 0.550 |
Why?
|
Thrombin | 1 | 2019 | 601 | 0.550 |
Why?
|
Aneurysm, False | 1 | 2019 | 264 | 0.550 |
Why?
|
Pneumoperitoneum | 1 | 2017 | 46 | 0.540 |
Why?
|
Cisplatin | 3 | 2024 | 1654 | 0.520 |
Why?
|
Fibrinogen | 1 | 2019 | 895 | 0.510 |
Why?
|
Suture Techniques | 1 | 2019 | 774 | 0.460 |
Why?
|
Prostatic Neoplasms | 7 | 2024 | 11090 | 0.460 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2023 | 5333 | 0.450 |
Why?
|
Propensity Score | 6 | 2021 | 1971 | 0.450 |
Why?
|
Brachytherapy | 1 | 2020 | 1218 | 0.410 |
Why?
|
Antineoplastic Agents | 5 | 2021 | 13631 | 0.400 |
Why?
|
Neoadjuvant Therapy | 6 | 2024 | 2895 | 0.390 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2024 | 633 | 0.370 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3940 | 0.350 |
Why?
|
Urinary Bladder | 5 | 2024 | 1155 | 0.350 |
Why?
|
Retrospective Studies | 25 | 2024 | 81537 | 0.340 |
Why?
|
Adenocarcinoma | 2 | 2019 | 6360 | 0.340 |
Why?
|
Neutropenia | 1 | 2014 | 894 | 0.320 |
Why?
|
Carcinoma | 1 | 2020 | 2311 | 0.320 |
Why?
|
Prostate-Specific Antigen | 4 | 2022 | 2463 | 0.300 |
Why?
|
Androgen Antagonists | 3 | 2021 | 1411 | 0.300 |
Why?
|
Survival Rate | 6 | 2021 | 12822 | 0.290 |
Why?
|
Urethra | 2 | 2021 | 406 | 0.290 |
Why?
|
Aged, 80 and over | 14 | 2024 | 59496 | 0.280 |
Why?
|
Nasolacrimal Duct | 1 | 2007 | 79 | 0.270 |
Why?
|
Monocytes | 1 | 2016 | 2591 | 0.270 |
Why?
|
Prostatectomy | 3 | 2022 | 1786 | 0.270 |
Why?
|
Muscles | 4 | 2023 | 1577 | 0.240 |
Why?
|
Aged | 23 | 2024 | 171163 | 0.240 |
Why?
|
Neoplasm Staging | 5 | 2024 | 11196 | 0.230 |
Why?
|
Humans | 52 | 2024 | 765926 | 0.230 |
Why?
|
Male | 32 | 2024 | 363815 | 0.230 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 3542 | 0.230 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3183 | 0.230 |
Why?
|
Cystoscopy | 2 | 2021 | 128 | 0.230 |
Why?
|
Kidney | 1 | 2019 | 7073 | 0.220 |
Why?
|
Administration, Intravesical | 2 | 2021 | 88 | 0.220 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6838 | 0.220 |
Why?
|
Pentose Phosphate Pathway | 1 | 2023 | 125 | 0.200 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1535 | 0.200 |
Why?
|
Prognosis | 7 | 2024 | 29890 | 0.200 |
Why?
|
Neoplasm Invasiveness | 7 | 2024 | 3599 | 0.190 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39228 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6503 | 0.180 |
Why?
|
Cohort Studies | 5 | 2021 | 41680 | 0.180 |
Why?
|
Kidney Diseases, Cystic | 1 | 2022 | 182 | 0.170 |
Why?
|
BCG Vaccine | 2 | 2021 | 380 | 0.170 |
Why?
|
Middle Aged | 18 | 2024 | 223016 | 0.170 |
Why?
|
Female | 20 | 2024 | 396141 | 0.160 |
Why?
|
Rewarming | 1 | 2019 | 64 | 0.160 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 619 | 0.160 |
Why?
|
Cell Line, Tumor | 4 | 2024 | 17060 | 0.150 |
Why?
|
Kidney Pelvis | 1 | 2020 | 191 | 0.150 |
Why?
|
Glycolysis | 1 | 2023 | 837 | 0.150 |
Why?
|
Urethral Obstruction | 1 | 2018 | 56 | 0.150 |
Why?
|
Urologic Surgical Procedures | 1 | 2021 | 281 | 0.150 |
Why?
|
Disease Progression | 3 | 2024 | 13614 | 0.150 |
Why?
|
Postoperative Complications | 2 | 2021 | 15802 | 0.150 |
Why?
|
Hypothermia | 1 | 2019 | 190 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4851 | 0.140 |
Why?
|
Risk Factors | 8 | 2022 | 74850 | 0.140 |
Why?
|
Muscle, Smooth | 1 | 2021 | 931 | 0.140 |
Why?
|
Leukocyte Count | 2 | 2020 | 1605 | 0.130 |
Why?
|
Treatment Outcome | 7 | 2022 | 65194 | 0.130 |
Why?
|
Cell Cycle Proteins | 2 | 2024 | 3431 | 0.130 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1729 | 0.110 |
Why?
|
Mice, Nude | 1 | 2020 | 3608 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2510 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2017 | 1695 | 0.110 |
Why?
|
Age Factors | 3 | 2019 | 18382 | 0.110 |
Why?
|
Drug Combinations | 1 | 2019 | 2075 | 0.110 |
Why?
|
Alkaline Phosphatase | 1 | 2016 | 855 | 0.110 |
Why?
|
Japan | 3 | 2024 | 1411 | 0.100 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 2141 | 0.100 |
Why?
|
Lymphocytes | 1 | 2020 | 2601 | 0.100 |
Why?
|
Radiation Dosage | 1 | 2020 | 1945 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 2455 | 0.090 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6209 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2057 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8603 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2020 | 2877 | 0.090 |
Why?
|
Mitoxantrone | 1 | 2011 | 148 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11858 | 0.090 |
Why?
|
Hemoglobins | 1 | 2016 | 1531 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2924 | 0.080 |
Why?
|
Renal Dialysis | 1 | 2019 | 1791 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2020 | 5300 | 0.080 |
Why?
|
Radiotherapy | 1 | 2014 | 1491 | 0.070 |
Why?
|
Body Weights and Measures | 1 | 2007 | 208 | 0.070 |
Why?
|
Neutrophils | 1 | 2020 | 3769 | 0.070 |
Why?
|
Prednisone | 1 | 2011 | 1566 | 0.060 |
Why?
|
Time Factors | 2 | 2017 | 40097 | 0.060 |
Why?
|
Smoking | 1 | 2021 | 9082 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2020 | 10426 | 0.060 |
Why?
|
Treatment Failure | 1 | 2011 | 2653 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15401 | 0.050 |
Why?
|
RNA-Binding Protein FUS | 1 | 2024 | 77 | 0.050 |
Why?
|
STAT1 Transcription Factor | 1 | 2024 | 340 | 0.050 |
Why?
|
Vinblastine | 1 | 2024 | 483 | 0.050 |
Why?
|
SOXB1 Transcription Factors | 1 | 2024 | 283 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7423 | 0.050 |
Why?
|
Signal Transduction | 2 | 2024 | 23597 | 0.050 |
Why?
|
Contrast Media | 2 | 2024 | 5330 | 0.040 |
Why?
|
Mice | 3 | 2024 | 81782 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4882 | 0.040 |
Why?
|
Adult | 5 | 2021 | 223088 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2024 | 998 | 0.040 |
Why?
|
Risk Assessment | 1 | 2019 | 24275 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 42510 | 0.040 |
Why?
|
Methotrexate | 1 | 2024 | 1719 | 0.030 |
Why?
|
Doxorubicin | 1 | 2024 | 2226 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2021 | 2476 | 0.030 |
Why?
|
Stroke Volume | 1 | 2011 | 5595 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2492 | 0.030 |
Why?
|
Animals | 3 | 2024 | 168735 | 0.030 |
Why?
|
RNA-Binding Proteins | 1 | 2024 | 1882 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 777 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2019 | 993 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2021 | 1182 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10611 | 0.030 |
Why?
|
Prostate | 1 | 2022 | 1758 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2022 | 20690 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2234 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2019 | 2255 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 12973 | 0.020 |
Why?
|
Endoscopy | 1 | 2018 | 1854 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10086 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12059 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3530 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9600 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12529 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6409 | 0.020 |
Why?
|
Child | 2 | 2018 | 80568 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5987 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14643 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 36547 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15878 | 0.010 |
Why?
|
Adolescent | 1 | 2007 | 88811 | 0.010 |
Why?
|
Prospective Studies | 1 | 2020 | 54807 | 0.010 |
Why?
|
Neoplasms | 1 | 2024 | 22340 | 0.010 |
Why?
|